Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 1/2 Terminated
42 enrolled
A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery
Phase 1/2 Terminated
8 enrolled
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Phase 1/2 Terminated
95 enrolled
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
53 enrolled 23 charts
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1/2 Terminated
175 enrolled
MGC018 With or Without MGA012 in Advanced Solid Tumors
Phase 1/2 Terminated
143 enrolled 33 charts
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies
Phase 1/2 Terminated
80 enrolled
AVID100 in Advanced Epithelial Carcinomas
Phase 1/2 Terminated
49 enrolled 19 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Phase 1/2 Terminated
87 enrolled 29 charts
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Phase 1/2 Terminated
222 enrolled 49 charts
Study of ALE.C04 in Patients With Head and Neck Cancer
Phase 1/2 Terminated
21 enrolled
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Phase 1/2 Terminated
12 enrolled 8 charts
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer
Phase 1/2 Terminated
3 enrolled 8 charts
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
JAVELIN Medley
Phase 1/2 Terminated
409 enrolled 108 charts
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Phase 1/2 Terminated
41 enrolled 18 charts
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Phase 1/2 Terminated
11 enrolled
Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
20 enrolled
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1/2 Terminated
99 enrolled 21 charts
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
Phase 1/2 Terminated
19 enrolled
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
Phase 1/2 Terminated
2 enrolled
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Phase 1/2 Terminated
14 enrolled 13 charts
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
Phase 1/2 Terminated
8 enrolled 10 charts
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
Phase 1/2 Terminated
48 enrolled 20 charts
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1/2 Terminated
6 enrolled 8 charts
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Phase 1/2 Terminated
20 enrolled
Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN
Phase 1/2 Terminated
25 enrolled 14 charts
A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer
Phase 1/2 Terminated
75 enrolled 23 charts
REVEAL
Phase 1/2 Terminated
64 enrolled 22 charts
RTX-224 Monotherapy in Patients With Solid Tumors
Phase 1/2 Terminated
7 enrolled
A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)
Phase 1/2 Terminated
11 enrolled 12 charts
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer
Phase 1/2 Terminated
12 enrolled
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
3 enrolled 12 charts
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Phase 1/2 Terminated
5 enrolled 8 charts
SYNERGY-001
Phase 1/2 Terminated
241 enrolled 23 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
COPAN-ORL06
Phase 1/2 Terminated
11 enrolled
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1/2 Terminated
179 enrolled 38 charts
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Phase 1/2 Terminated
6 enrolled 12 charts
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Phase 1/2 Terminated
66 enrolled
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Phase 1/2 Terminated
19 enrolled 13 charts
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Phase 1/2 Terminated
4 enrolled
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase 1/2 Terminated
78 enrolled 19 charts